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2013.01.0Abstract Background: The monoclonal antibodies (mAbs) that target the epidermal growth fac-
tor receptor (EGFR) had expanded the range of treatment options for metastatic colorectal cancer.
However, such type of treatment was shown to be ineffective if there is K-ras mutation. In most
previous studies K-ras gene mutation was mainly assessed by PCR.
Aim: Our work is designed to detect K-ras protein expression by immunohistochemistry (IHC)
aiming to reach a preliminary method that could be conﬁrmed by PCR and considered an alterna-
tive way for the detection of K-ras aberration. We are also aiming to ﬁnd a relation between K-ras
protein expression and K-ras gene mutation.
Materials and methods: Parafﬁn embedded tissue samples from 26 metastatic colorectal cancer
(mCRC) patients were analyzed for K-ras protein expression by IHC using Rap1A polyclonal anti-
body. Staining patterns were subjectively assessed and correlated with clinicopathological features.
The results were statistically evaluated using the Chi-square test.
Results: K-ras cytoplasmic positivity was observed in 42.3% of cases. The positivity was either
strong in 26.9% or moderate in 15.4%. With respect to adenocarcinoma variants, 50% of cases were
positive for K-ras protein expression while all mucinous and signet ring types were negative. The pos-
itivity was noted in 50% of moderately differentiated GII colorectal carcinomas as compared with
38.9% in poorly differentiated GIII. Positive staining was observed in 40% of cases with positive223316657/+20 2 38354686;
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52 M.T. Elsabah, I. Adellymph node metastasis while in the absence of nodal metastasis the positivity was 45.5%. No signif-
icant correlation was found between clinicopathological parameters and K-ras staining results.
Conclusion: IHC may compliment PCR in the detection of K-ras mutation.
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In a cancer pathology registry done by National Cancer
Institute, Cairo University, colorectal cancer (CRC) had a
relative frequency of 5% of the total estimated cancers and
29% of gastrointestinal malignancies with male predominance
ratio of 3:1. According to the study of 427 cases, more than 1/3
of cases were under the age of 45 (early onset) with large tumor
size at presentation [1]. Colorectal cancer is a major cause of
cancer mortality and morbidity worldwide, representing
8.9% of all cancers [2]. It constituted the third most common
cancer among men and women, following breast, lung and
prostate. CRC was claimed as the second most common cause
of cancer-related death among patients in the United Kingdom
and the United States [3].
Despite continuing advances in therapeutic strategies,
recurrence rates of CRC are still high, with more prevalence
in rectal rather than colon cancer with ratios of 33% and
19%, respectively [4].
Distant metastasis is the main cause of death in CRC pa-
tients. Surgical resection remains the only potentially curative
option for patients with metastatic CRC. However, curative
resection is possible in <25% of patients with stage IV disease
[5].
The ras family of proto-oncogenes forms an important sub-
class of the GTP-binding proteins. The ras protein acts as a
signal transducer from membrane receptor (e.g. growth factor
receptor) to the nucleus, thus regulates growth and differenti-
ation [6]. The ras gene family encodes similar 21-kD protein
(p21ras). Aberrations in ras genes lead to increased and uncon-
trolled cell proliferation and malignant transformation. The
most exhaustively worked ras gene in colorectal cancer is K-
ras [7].
On its activation, the K-ras protein is capable of turning off
the signaling pathway by catalyzing hydrolysis of guanosine
triphosphates to guanosine diphosphates. The most common
K-ras mutations (approximately 90%) are found in codons
12 and 13. They are activation mutations, leading to continu-
ous activation of downstream pathways [8].
Mutant, activated forms of K-ras proteins have an im-
paired intrinsic GTPase activity, which renders the protein
resistant to inactivation by regulatory GTPase-activating pro-
teins [9].
Mutations of the K-ras gene have been identiﬁed in tissues
from both colonic adenoma and carcinoma cases, but at much
lower frequencies in adenoma tissues than in carcinoma tissues
[10].
K-ras mutation occurs in 30–50% of CRC and has been
suggested to be associated with proliferation and decreased
apoptosis [11].
Epidermal growth factor (EGF) is part of a complex net-
work of growth factors and receptors that together help to
modulate the growth of cells. Many types of cancer haveoveractive signaling through the epidermal growth factor
system [12].
The EGFR controls cell differentiation, proliferation and
angiogenesis. It is expressed in 80% of colorectal cancers [13].
EGFR over expression has been suggested as a factor of
poor prognosis and associated with a more aggressive clinical
progression [14].
Positive expression of EGFR as shown by IHC is not pre-
dictive of response to EGFR inhibitors. It is now clear that tu-
mor growth can be driven by the constitutive activation of
signaling pathways downstream of the EGFR, such as the
RAS-MAPK-PI3K pathway regardless of whether the EGFR
is activated or blocked [15].
Targeted therapy is considered recently a promising way to
cure cancer. K-ras mutation had emerged as an important pre-
dictive marker of resistance to anti EGFR monoclonal anti-
body treatment. However, among colorectal tumors carrying
wild-type K-ras, mutation of B-raf or PIK3CA or loss of
PTEN expression may be associated with resistance to
EGFR-targeted monoclonal antibody treatment [16].
The monoclonal antibodies cetuximab and panitumumab
have been developed to target EGFR [17]. Improved response
rates and prolonged time to metastasis/survival have been
demonstrated with the currently registered EGFR blocking
antibodies [18].
The anti-EGFR monoclonal antibodies are approved in the
United States for treatment of mCRC refractory to chemo-
therapy but are not recommended for use in patients with
mutations in K-ras codons 12 or 13 [19].
In metastatic colorectal cancer, EGFR instructs the cancer
cell to reproduce and metastasize; blocking the EGFR stops
this malignant signaling. However, in patients with mutant
K-ras, the signaling continues despite EGFR therapy [20].
Determining tumor K-ras status before initiating treatment
with an anti-EGFR monoclonal antibody is widely recom-
mended with restriction of such treatment to patients with tu-
mor bearing wild-type K-ras [21].
Therefore, to explore the effect of mutations of K-ras gene
on malignant biologic behaviors of rectal cancer and its clinical
signiﬁcance, the mutation patterns of codons 12 and 13 of K-
ras gene were detected by PCR [22].
PCR based assays constitute the cornerstone for clinical K-
ras testing since these analyses allow high-throughput testing
and have a favorable sensitivity, also in samples with low tu-
mor cell content [23].
For investigating the relation between K-ras mutation and
its protein ras p21 expression, K-ras codons 12 and 13 point
mutations were examined by direct sequence analysis, whereas
the ras p21 expression was evaluated using immunohistochem-
istry [7] and [24].
Immunohistochemistry is widely used to understand the
distribution and localization of biomarkers and differentially
expressed proteins in different parts of a biological tissue.
Figure 1 Adenocarcinoma with strong (3+) brown cytoplasmic
staining for K-ras protein (X400).
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therapy, by detecting the presence or elevated level of molecu-
lar target [25].
Materials and methods
Parafﬁn embedded tissue samples from 26 CRC patients with
liver metastasis were collected from a private lab and screened
for K-ras protein expression by the immunohistochemical
method using Rap1A polyclonal antibody. The clinicopatho-
logical data including age, sex, microscopic types, histological
grade and lymph node status were collected for statistical anal-
ysis. All the selected cases were metastatic to reﬂect the rou-
tinely ordered K-ras mutation analysis when EGFR inhibitor
therapy was considered.
Immunohistochemistry
Sections (5 lm) were deparafﬁnized in xylene. Endogenous per-
oxidase was blocked by 0.3% hydrogen peroxide–methanol for
20 min. After immersing the sections in alcohol they were rehy-
drated. Antigen retrieval was performed by heating the sections
at 100 C in 10 ml citrate buffer (pH 6.0) for 10 min. After a
short rinse in phosphate-buffered saline (PBS), sections were
incubated overnight at room temperature with antibody
Rap1A also known as Krev-1 and smg p21 (Rabbit anti-human
polyclonal antibody LSBio Catalog ID: LS-C49691). After sev-
eral washing steps in PBS, sections were incubated for 30 min
with labeled second antibody. PBS washings were followed
by incubation for 1 h with a complex of biotinylated horse rad-
ish peroxidase and Streptavidin, diluted 1:100 in PBS. Staining
was developed in PBS containing 0.05% 3,3-diaminobenzidine
tetrahydrochloride and 0.02% hydrogen peroxide. Sections
were counterstained with hematoxylin, dehydrated with etha-
nol, cleared in xylene and mounted with malinol under a cover-
slip. The slides were then visualized under a light microscope.
Tissue samples to which no primary antibody had been added
were used as negative controls.
Evaluation of the result
Cytoplasmic IHC staining of K-ras protein was scored subjec-
tively under light microscope by two observers and the per-
centage of stained tumor cells (brown color) was expressed
depending on previously established criteria of Akkiprik
et al. [7] and Sammoud et al. [24] as follows: 3(+) when the
majority of cells (>75%) were stained strongly, 2(+) when
25–50% of cells were stained moderately, and 1(+) when the
staining was focal (<25%) and weak. Scores 2(+) and 3(+)
were considered as expression of K-ras protein while score
1(+) and non-stained cells were considered as negative.
Statistics
The various clinicopathological parameters and K-ras
immunostaining results were statistically examined using the
Chi-square test for any signiﬁcant relation.
Results
In this study 26 metastatic CRC cases were included. They had
successful immunostaining of the K-ras protein. The age of thepatients ranged from 46 to 80 years with a mean age of 63.
Among the 26 cases enrolled in this study, 18 (69.2%) cases
were males and 8 (30.8%) were females. The male to female ra-
tio was 2.3:1. As regards the microscopic types, 22 (84.6%)
cases were adenocarcinoma, 2 (7.7%) were mucinous carci-
noma and 2 (7.7%) were signet ring carcinoma. Concerning
the histological grading, 8 (30.8%) cases were moderately dif-
ferentiated GII and 18 (69.2%) were poorly differentiated
GIII. All our cases were metastatic Dukes’ stage D. Lymph
node metastases were positive in 15 (57.7%) cases while free
nodal tissues were observed in 11 (42.3%).
IHC results
Among the 26 cases subjected to K-ras immunostaining, 11
(42.3%) cases were positive. The positivity was either strong
3(+) in 7 (26.9%) cases (Fig. 1) or moderate 2(+) in 4
(15.4%) cases (Fig. 2). The remaining 15 (57.7%) cases were
negative (3 cases with score 1(+) and 12 unstained cases) (Ta-
ble 1).
Clinical correlation
Our study did not reveal any statistical correlation between age
and sex and K-ras immunostaining. K-ras positivity was de-
tected in 11 (50%) out of 22 glandular adenocarcinoma cases
(7 strong and 4 moderate) while the remaining 11 (50%) cases
were negative. The four cases of mucinous (2) and signet ring
(2) carcinomas were all negative for K-ras immunostaining.
However, the number of cases in signet ring and mucinous
types was small and accordingly no statistical difference was
calculated (Table 2). Among the 8 (30.8%) cases of moderately
differentiated GII adenocarcinoma, 4 (50%) cases were posi-
tive (4 strong) and 4 (50%) were negative. Seven (38.9%) out
of 18 cases of poorly differentiated adenocarcinoma GIII were
found positive (3 strong and 4 moderate) while the remaining
11 (61.1%) cases were negative. There was no signiﬁcant differ-
ence between the two grades in K-ras expression (p= 0.683)
(Table 3).
In 15 cases with nodal metastasis, K-ras positivity was
found in 6 (40%) cases (3 strong and 3 moderate), while the
Figure 2 Adenocarcinoma with negative cytoplasmic staining
for K-ras protein (X400).
Table 1 K-ras immunostaining in metastatic colorectal
carcinoma.
Frequency Percent (%)
Negative 15 57.7
Positive 11 42.3
Strong 7 26.9
Moderate 4 15.4
Total 26 100.0
Table 2 Relation between microscopic types and K-ras
immunostaining.
Microscopic type K-ras Total
Positive
(strong + moderate)
Negative
(weak + negative)
Glandular adenocarcinoma
Number 11 11 22
% 50% 50% 100.0%
Signet ring
Number 0 2 2
% .0% 100% 100.0%
Mucinous
Number 0 2 2
% .0% 100% 100%
Total
Number 11 15 26
% 42.3% 57.7% 100.0%
Table 3 Relation between histological grading and K-ras
immunostaining.
Histological grade K-ras Total
Positive
(strong + moderate)
Negative
(weak + negative)
Grade II
Number 4 4 8
% 50% 50% 100.0%
Grade III
Number 7 11 18
% 38.9% 61.1% 100.0%
Total
Number 11 15 26
% 42.3% 57.7% 100.0%
Table 4 Relation between lymph node metastasis and K-ras
immunostaining.
Lymph node
metastasis
K-ras Total
Positive
(strong + moderate)
Negative
(weak + negative)
Positive lymph nodes
Number 6 9 15
% 40.0% 60.0% 100.0%
Negative lymph nodes
Number 5 6 11
% 45.5% 54.5% 100.0%
Total
Number 11 15 26
% 42.3% 57.7% 100.0%
54 M.T. Elsabah, I. Adelother 9 (60%) cases were negative. K-ras positive staining was
found in 5 (45.5%) cases (4 strong and one moderate) out of 11
nodal free cases while the remaining 6 (54.5%) cases were neg-
ative. There was no signiﬁcant difference between the node sta-
tus and K-ras expression (p= 1.000) (Table 4).Discussion
In comparison with previous researches that aimed to discover
K-ras gene mutation using PCR techniques taking into consid-
eration the high cost values and codon speciﬁc properties of
this method, our work focused on the detection of K-ras pro-
tein expression by IHC. Immunohistochemistry was regarded
as cost saving, not speciﬁc for codons and a preliminary result
that could be conﬁrmed by PCR. However, in our work IHC
has a limitation in which anti-ras polyclonal antibody can re-
act with both wild and mutant K-ras proteins.
Using Rap1A polyclonal antibody, we detected K-ras pro-
tein expression in 42.3% of our cases. Akkiprik et al. [7] re-
vealed expression of ras p21 in 76% of samples tested with
Ras Ab-1 polyclonal antibody.
In the present study, we detected K-ras protein expression
in 42.3% of cases; this was close to the studies that detected
the mutation at codons 12 and 13 of K-ras protein in 39%
and 46% [23–26]. However, other studies found the positivity
in 36.5%, 32.8%, 23.07% and 11% [27-11-24-7]. Akkiprik
et al. [7] reported some drawbacks in the mutation analysis,
as mutation sites which are codon speciﬁc, have ethnic varia-
tions and differences in the dietary components and lifestyle
factors.
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positivity in other studies may denote sample representation of
IHC versus gene mutation. Our results can be used as a nu-
cleus for further investigation to detect K-ras mutation using
PCR in the same group of patients aiming to ﬁnd a relation be-
tween the two forms of ras aberrations and disclose an alterna-
tive way for detection of K-ras mutation depending on IHC.
Analysis of age and sex of our patients did not reveal any
signiﬁcant correlation with K-ras protein expression. Our re-
sults were in agreement with other studies who did not report
any relation between age and sex distribution and K-ras gene
mutation [7, 11, 27].
In this study K-ras expression was detected in 50% of glan-
dular adenocarcinoma cases. Although all cases of mucinous
and signet ring variants were negative for immunostaining, it
was not possible to rely on statistical analysis results because
of the small number of cases. Liu et al. [11] emphasized that
the presence of mucinous differentiation did not make a differ-
ence between the wild-type K-ras containing and K-ras mu-
tated CRCs. On the other hand, Akkiprik et al. [7] and
Okulczyk et al. [27] found that in the mucus-secreting tumors,
mutation incidence detected by PCR methods was signiﬁcant
or close to signiﬁcant.
In this work K-ras positivity was estimated in 50% of GII
moderately differentiated adenocarcinoma while in GIII
poorly differentiated adenocarcinoma the ratio was 38.9%.
There was no signiﬁcant difference between the two histologi-
cal grades in K-ras expression (p= 0.683).
Our results were in accordance with other results who did
not ﬁnd any signiﬁcant correlation between K-ras mutation
and the histological grades [7-11-26-27].
Our cases were metastatic CRC (Dukes’ stage D). Akkiprik
et al. [7] and Okulczyk et al. [27] analyzed Dukes scale against
K-ras mutation using PCR methods. They did not note any
signiﬁcant difference between Dukes scale and K-ras mutation.
Other studies emphasized that the appearance of distant
metastases was not related to K-ras mutations [11–26].
With respect to nodal metastases and their relation to K-ras
staining, our results showed positive staining in 40% of cases
with nodal involvement vs 45.5% in cases with free nodal sta-
tus. There was no signiﬁcant difference between nodal involve-
ment and K-ras staining (p= 1.000). These results were in
agreement with Schimanski et al. [26] and Liu et al. [11]; They
did not ﬁnd any signiﬁcant difference between nodal metastasis
and K-ras mutation.
Sammoud et al. [24] showed that the expression of ras p21
was correlated with the advanced age of patients. However,
our results were in agreement with Akkiprik et al. [7] who re-
vealed that none of the clinicopathological parameters were re-
lated to K-ras protein overexpression. They also emphasized
that there was no signiﬁcant correlation between ras p21 over-
expression and K-ras mutations due to the fact that Ras Ab-1
polyclonal antibody used in their IHC analysis detects all over-
expressed forms of the protein, including the mutant or wild-
type.Acknowledgement
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